Literature DB >> 29345295

Upregulation of the BDNF/TrKB pathway promotes epithelial-mesenchymal transition, as well as the migration and invasion of cervical cancer.

Yuan Yuan1, Hai-Qiong Ye2, Qian-Chuan Ren2.   

Abstract

Brain-derived neurotrophic factor (BDNF) has previously been demonstrated to be associated with several types of cancer. In addition, its receptor, tropomyosin related kinase B (TrkB) is involved in tumor invasion and metastasis. Epithelial-mesenchymal transition (EMT) is associated with metastasis in cancers. Thus, The aim of the present study was to examine whether BDNF/TrKB expression is linked to a poor survival and the acquisition of the EMT phenotype in cervical cancer. We found that a high positive expression of BDNF/TrKB was associated with poor survival in cervical cancer. Our results revealed that high expression levels of BDNF/TrKB were observed in cervical cancer compared to normal cells. Importantly, we demonstrated that the silencing of TrKB suppressed the activation of EMT via the downregulation of N-cadherin, vimentin, matrix metalloproteinase (MMP)2 and MMP9, and the upregulation of E-cadherin and tissue inhibitor of metalloproteinases (TIMP)2, which resulted in suppressed cell proliferation, migration and invasion. Furthermore, high phosphorylation levels of ERK and Akt were observed in the cervical cancer cells, while these levels were decreased in the cells in which TrKB was knocked down. On the whole, these findings suggest that the BDNF/TrKB pathway is a promising target for the prevention of tumor proliferation, invasion, metastasis and EMT in cervical cancer cells.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29345295     DOI: 10.3892/ijo.2017.4230

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

Review 1.  Interactions Among Brain-Derived Neurotrophic Factor and Neuroimmune Pathways Are Key Components of the Major Psychiatric Disorders.

Authors:  Nikolay Mehterov; Danail Minchev; Maria Gevezova; Victoria Sarafian; Michael Maes
Journal:  Mol Neurobiol       Date:  2022-06-03       Impact factor: 5.682

Review 2.  Stress Hormones: Emerging Targets in Gynecological Cancers.

Authors:  Guoqiang Chen; Lei Qiu; Jinghai Gao; Jing Wang; Jianhong Dang; Lingling Li; Zhijun Jin; Xiaojun Liu
Journal:  Front Cell Dev Biol       Date:  2021-07-09

3.  Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cells.

Authors:  Min Kang; Kay Yi Chong; Tobias M P Hartwich; Fangfang Bi; Allyson K Witham; David Patrick; Madeline J Morrisson; Sarah L Cady; Alexandra P Cerchia; Dawn Kelk; Yifei Liu; Jonah Nucci; Oluwagbemisola Madarikan; Daiki Ueno; Brian M Shuch; Yang Yang-Hartwich
Journal:  Oncogenesis       Date:  2020-05-29       Impact factor: 7.485

4.  Downregulation of Krüppel‑like factor 1 inhibits the metastasis and invasion of cervical cancer cells.

Authors:  Bisheng Zhu; Qisheng Liu; Qi Han; Bohang Zeng; Jingqi Chen; Qiuju Xiao
Journal:  Mol Med Rep       Date:  2018-08-20       Impact factor: 2.952

5.  Proliferative role of BDNF/TrkB signaling is associated with anoikis resistance in cervical cancer.

Authors:  Yuan Yuan; Hai-Qiong Ye; Qian-Chuan Ren
Journal:  Oncol Rep       Date:  2018-06-20       Impact factor: 3.906

Review 6.  Angiogenesis in Gynecological Cancers: Role of Neurotrophins.

Authors:  Maritza P Garrido; Ignacio Torres; Margarita Vega; Carmen Romero
Journal:  Front Oncol       Date:  2019-09-19       Impact factor: 6.244

7.  MiR-489-3p inhibits cell proliferation, migration, and invasion, and induces apoptosis, by targeting the BDNF-mediated PI3K/AKT pathway in glioblastoma.

Authors:  Bo Zheng; Tao Chen
Journal:  Open Life Sci       Date:  2020-05-29       Impact factor: 0.938

8.  TrkB-Targeted Therapy for Mucoepidermoid Carcinoma.

Authors:  Vivian P Wagner; Manoela D Martins; Esra Amoura; Virgilio G Zanella; Rafael Roesler; Caroline B de Farias; Colin D Bingle; Pablo A Vargas; Lynne Bingle
Journal:  Biomedicines       Date:  2020-11-24

9.  Doxorubicin inhibits osteosarcoma progression by regulating circ_0000006/miR-646/ BDNF axis.

Authors:  Abulimiti Amuti; Dehu Liu; Ayiguli Maimaiti; Yao Yu; Yalikun Yasen; Haoguang Ma; Rui Li; Shurong Deng; Fei Pang; Youliang Tian
Journal:  J Orthop Surg Res       Date:  2021-10-30       Impact factor: 2.359

10.  Concomitant attenuation of HMGCR expression and activity enhances the growth inhibitory effect of atorvastatin on TGF-β-treated epithelial cancer cells.

Authors:  Katsuhiko Warita; Takuro Ishikawa; Akihiro Sugiura; Jiro Tashiro; Hiroaki Shimakura; Yoshinao Z Hosaka; Ken-Ichi Ohta; Tomoko Warita; Zoltán N Oltvai
Journal:  Sci Rep       Date:  2021-06-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.